{"disease":{"id":"systemic-lupus-erythematosus-sle","name":"systemic lupus erythematosus sle"},"drugs":{"marketed":[{"drug_id":"anifrolumab","indication_name":"Moderate to severe systemic lupus erythematosus (SLE)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Saphnelo","generic_name":"ANIFROLUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor 1","drug_class":"Type I Interferon Receptor Antagonist [EPC]","quality_score":59,"revenue":"700","mechanism":"Saphnelo blocks the action of interferon alpha/beta, a protein that triggers an immune response."},{"drug_id":"anifrolumab-fnia","indication_name":"Moderate to severe systemic lupus erythematosus (SLE)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SAPHNELO","generic_name":"ANIFROLUMAB-FNIA","company_name":"ASTRAZENECA AB","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor 1","drug_class":"Type I Interferon Receptor Antagonist [EPC]","quality_score":17,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06927219","title":"Research Accelerated by You Lupus Registry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Lupus Foundation of America","has_results":false},{"nct_id":"NCT02782039","title":"Register of Patients With Anti-Phospholipids Syndrome (APS) and/or Systemic Lupus Erythematosus (SLE)","phase":"","overall_status":"COMPLETED","enrollment_count":868,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05352919","title":"An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":864,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT07209540","title":"European LUpuS Inception-Cohort Developing initiATivE","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":700,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT07087912","title":"Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":477,"lead_sponsor_name":"University of Sao Paulo General Hospital","has_results":false},{"nct_id":"NCT03978520","title":"A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":341,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT05000216","title":"COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":258,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT04058028","title":"Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":244,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT06308978","title":"A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":244,"lead_sponsor_name":"Fate Therapeutics","has_results":false},{"nct_id":"NCT07175285","title":"A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants","phase":"","overall_status":"RECRUITING","enrollment_count":223,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT02811094","title":"LUMIER² Study : LUpus Molecular Immunomonitoring to Evaluate the Risk of Relapse","phase":"NA","overall_status":"TERMINATED","enrollment_count":210,"lead_sponsor_name":"Assistance Publique Hopitaux De Marseille","has_results":false},{"nct_id":"NCT07332481","title":"A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":202,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":false},{"nct_id":"NCT06314282","title":"INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06888973","title":"Mesenchymal Stem Cells Infusion in Patients With Autoimmune Diseases","phase":"PHASE1, PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":200,"lead_sponsor_name":"National Institute of Blood and Marrow Transplant (NIBMT), Pakistan","has_results":false},{"nct_id":"NCT07185269","title":"The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":198,"lead_sponsor_name":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT05688696","title":"Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":186,"lead_sponsor_name":"Beijing InnoCare Pharma Tech Co., Ltd.","has_results":false},{"nct_id":"NCT04451772","title":"A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":185,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02804763","title":"A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":182,"lead_sponsor_name":"UCB Biopharma S.P.R.L.","has_results":true},{"nct_id":"NCT06626945","title":"AZAHAR Study To Describe Anifrolumab in a Real-World Setting","phase":"","overall_status":"COMPLETED","enrollment_count":152,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05724940","title":"Comparison of Clinical and Serological Differences Among Juvenile, Adult, and Late-onset Systemic Lupus Erythematosus","phase":"","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Sohag University","has_results":false},{"nct_id":"NCT06625671","title":"A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE Participants","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":148,"lead_sponsor_name":"DualityBio Inc.","has_results":false},{"nct_id":"NCT07281105","title":"EG-501 for Cognitive Impairment in Neuropsychiatric SLE (NPSLE): Efficacy and Safety Study","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":131,"lead_sponsor_name":"Evergreen Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03031925","title":"Detection of Annexin A2 in Systemic Lupus Erythematosus","phase":"NA","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Centre Hospitalier Universitaire, Amiens","has_results":false},{"nct_id":"NCT07447986","title":"To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Hangzhou Sumgen Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT03093402","title":"JBT-101 in Systemic Lupus Erythematosus (SLE)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":109,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT03656562","title":"Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":107,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT01946880","title":"Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":102,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT05567198","title":"Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","has_results":false},{"nct_id":"NCT06936007","title":"Hematological Manifestations in Systemic Lupus Erythematosus Patients","phase":"","overall_status":"COMPLETED","enrollment_count":99,"lead_sponsor_name":"Patan Academy of Health Sciences","has_results":false},{"nct_id":"NCT03122431","title":"Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"University of Sao Paulo General Hospital","has_results":true},{"nct_id":"NCT06032923","title":"Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":78,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT03626311","title":"Omega-3 Replacement With Krill Oil in Disease Management of SLE","phase":"NA","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"Aker BioMarine Human Ingredients AS","has_results":false},{"nct_id":"NCT04461158","title":"CCCR Lupus Patient Navigator Program","phase":"NA","overall_status":"COMPLETED","enrollment_count":75,"lead_sponsor_name":"Medical University of South Carolina","has_results":true},{"nct_id":"NCT06647069","title":"A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":62,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT07085676","title":"Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Polina Stepensky","has_results":false},{"nct_id":"NCT07041801","title":"Treatment of Systemic Lupus Erythematosus With Human Umbilical Cord Mesenchymal Stem Cells","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":58,"lead_sponsor_name":"Shenzhen Beike Bio-Technology Co., Ltd.","has_results":false},{"nct_id":"NCT06335979","title":"An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06677801","title":"Immune Cell Subsets in SLE Patients Treated with Telitacicept","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT03492255","title":"CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid","phase":"NA","overall_status":"TERMINATED","enrollment_count":49,"lead_sponsor_name":"University of Sao Paulo General Hospital","has_results":false},{"nct_id":"NCT05984251","title":"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT06144710","title":"SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Hangzhou Sumgen Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT05866861","title":"A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Cugene Inc.","has_results":false},{"nct_id":"NCT06659068","title":"Efficacy of Seluang Fish Oil (Rasbora Argyrotaenia) and Synbiotics Supplementation on CD4+CD25+ Foxp3+ T-regulator Cells, IL17/IL-10 Ratio, and Disease Activity in Systemic Lupus Erythematosus Patients","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Universitas Sriwijaya","has_results":false},{"nct_id":"NCT07252141","title":"miR-101-3p and Autotaxin in SLE Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Eman Mohamed Shawky","has_results":false},{"nct_id":"NCT07071220","title":"Efficacy of Vitamin C Supplementation on Serum IL-6 Levels and Disease Activity in Systemic Lupus Erythematosus Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Universitas Sriwijaya","has_results":false},{"nct_id":"NCT07083622","title":"Efficacy of Vitamin C Supplementation on Malondialdehid Levels and Disease Activity in SLE Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Universitas Sriwijaya","has_results":false},{"nct_id":"NCT07071233","title":"Efficacy of Vitamin C Supplementation on Serum TNF-α Levels and Disease Activity in SLE Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Universitas Sriwijaya","has_results":false},{"nct_id":"NCT07331272","title":"A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":38,"lead_sponsor_name":"Nanjing Legend Biotech Co.","has_results":false},{"nct_id":"NCT06720584","title":"Whole Health Empowerment for Endotypes of Lupus: Improving Quality of Life in SLE","phase":"NA","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT06010472","title":"An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Changhai Hospital","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}